Read the details / Briefing
Read the evidence behind a peptide-care offer
Find source pages to check a medicine, a licence, an online visit or a bill. Each link has a short note explaining what it can tell you.
Product and payment rules: as of September 26, 2026.
Match the source to the question
A medicine’s status
Look for the exact medicine and its form: pill or injection, rather than a broad claim about peptides.
A licence
Use the relevant state board’s records. The medical and pharmacy checks answer different questions.
A prescribing rule
Ask which rule applies where you will physically be at the time of care. Check when that rule was last reviewed.
A price or benefit
Read who qualifies, which pills or injections are included and when the offer ends.
Reading notes
- FDA: why medicines are made to order
With compounding, a medicine is made to suit a patient’s needs; the Food and Drug Administration (FDA) explains why this may be needed. It explains why those medicines differ from approved products.
- FDA: unpacking an approval claim
Read why having a pharmacy’s name on a registration list does not mean FDA approved its medicines.
- Medical boards: the remote-care standard
The Federation of State Medical Boards provides guidance to the state bodies that license doctors. Read about the duty to assess your health and arrange any tests or exam you need. This is guidance; states set the rules that can be enforced.
- Medical boards: patient-led treatment menus
The guidance says a prescription decision needs more than an item selected from a treatment menu. It also requires a way for patients to raise questions of their own.
- Medical boards: find the state record
Links to the state bodies that license doctors. Check the doctor’s licence status and look for public records of action against them. A record without such action gives no measure of the quality of their care.
- FDA: find a pharmacy licence record
The lookup page points to state pharmacy boards. Being listed establishes a licence, rather than verifying each medicine or dispensing decision.
- FDA: compounding after a shortage ends
Read how being on FDA’s national shortage list changes the limits on making copies of a medicine. Stock running out at one pharmacy cannot place that medicine on the national list.
- FDA: concerns with unapproved weight products
Read about products marked “research use only”, false pharmacy names and delivery problems. The page discusses particular medicines and practices, rather than every peptide.
- CMS: the temporary Medicare payment route
The Centers for Medicare & Medicaid Services describes the Medicare GLP-1 Bridge, a temporary program for certain weight-care medicines. Read which medicines it covers and who qualifies before counting on its $50 monthly payment.
Read what a warning letter or problem report can tell you
An FDA warning letter records the concerns FDA held about a company at the time of writing. Later discussions with the company may change whether those issues are still unresolved.
Reporting a problem with a medicine does not establish that the medicine was its cause. The reports cannot show how often the problem happens.